ATI 2231
Alternative Names: ATI-2231Latest Information Update: 07 Mar 2025
At a glance
- Originator Aclaris Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bone disorders
- Discontinued Solid tumours
Most Recent Events
- 07 Mar 2025 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (PO)
- 29 Nov 2023 Aclaris Therapeutics withdraws the phase I trial due to sponsors decision in Solid tumours (Late-stage disease) in USA (PO) (NCT05791474)
- 13 Nov 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO)